Because of its comparatively recent evolution, Homo sapiens exhibit relatively little within-species genomic diversity.
V ariability in drug response is typical of cardiovascular therapies (1) and may be related to common genetic variation (1-3), operationally defined as a polymorphism with a minor allele frequency of $1% (4). Race-associated differences in cardiovascular disease natural history and drug response are well known and may be associated with genetic variation in drug targets or pharmacokinetics (2) that can potentially explain variability in racially based responses to heart failure therapies.
We review and provide new information on raceassociated differences in heart failure natural history and therapeutic responses associated with common genetic variation. The information is confined to heart failure with reduced left ventricular ejection fraction (HFrEF, or HF), and race comparisons are made between subjects of Sub-Saharan African ancestry (AA) and those of European ancestry (EA) populations, regardless of geographic location. The overall aim of this review was to explore the hypothesis that reported racial differences in HF natural history or therapeutic response are influenced by differences in genetic variations in relevant cardiac myocyte neurohormonal signaling mechanisms.
RACE AND GENETIC VARIATION
An argument for a genetic basis for raceassociated differences in disease natural history or therapeutic response is predicated on the idea that different frequencies of genetic variants among racial groups may lead to differentiated outcomes among those groups.
Genetic alteration of a disease or therapeutic phenotype within a racially defined population is dependent on: 1) the frequency of the polymorphism in that population;
2) the difference in the allele frequency of the polymorphism between the indicated population and a general, non-racially selected population; and 3) the extent of the biological or pharmacologic effect of the polymorphism on the disease or therapeutic phenotype.
Extrapolating racial identity from common attributes such as skin color can be problematic due to the assumption that physical characteristics are a proper proxy for variations in biologic phenotype-modifying, non-anthropomorphic genes. Nevertheless, extensive clinical experience supports the fact that phenotype heterogeneity in disease risk, prognosis, and response to therapy can be attributed to selfidentified race, and it is appropriate to explore the extent to which genetic variation contributes to these differences (5, 6) . Understanding the underlying genetic basis of such heterogeneity will help devise new drugs, devices, and diagnostics that improve outcomes.
Genetic diversity in humans is relatively low compared with other species, including other primates (7) . This is generally attributed to Homo sapiens' relatively recent evolution in East Africa approximately 200,000 years ago, and the subsequent immigration of modern populations from Africa in the past 100,000 years (6) . Based on the first detailed single-nucleotide polymorphism (SNP) map of the human genome, encompassing 1.42 million variants occurring every 1.9 kb, humans were estimated to be 99.6% to 99.8% identical at the nucleotide level (6, 8) . The more recent 1000 Genomes Project, in which the goal is to identify pan-genomic and coding region variations down to respective allele frequencies of 1% and 0.1%, identified in its AA populations exhibit greater degrees of genetic variation than non-African cohorts (10, 11) . Given that modern European and Asian populations descended from founder groups that diverged from ancestral African populations, it is expected that genetic diversity in non-African groups would be lower because ancestral founder populations would contain only a subset of the total African variation. However, most of the genetic variations in African populations can also be found in non-African populations. Overall, 10% to 15% of all human genetic variation is explained by differences among Sub-Saharan Africans, Northern Europeans, and East Asians. Stated another way, approximately 85% to 90% of known variation is captured by studying any 1 of the 3 "major" population groups (Africa, Asia, and Europe), and only an additional 10% to 15% can be ascertained by inclusion of the other 2 groups (12). Thus, genetic variation among populations is only slightly more different than variation within a given population (13) .
These data have relevance for the evaluation of genetic variations related to health and disease. A priori, for any given variant there is an increased probability of it being represented in an AA versus a non-AA population. Furthermore, for any variant locus shared between AA and non-AA populations, the observed allele frequencies may differ, sometimes widely, between racial populations. 
have the minor allele in the heterozygous or homozygous state. Therefore, one can readily appreciate that skin color would be a poor method of determining whether a person carries the minor allele for these polymorphisms.
Despite widespread variation in the frequency of various genetic markers, the associated odds ratios for disease risk in different racial groups appears to be less variable (14) . However, data for HF disease progression and therapeutics show there is good evidence that racially based pharmacogenetic differences exist for both effectiveness and safety. Online Table 1 Consensus coding sequences are shown for ADRB1 (A) and ADRB2 (B) (43). Amino acid changes resulting from nonsynonymous single nucleotide polymorphisms (SNPs) are in yellow, and unchanged amino acids at the site of synonymous SNPs are in red. Polymorphisms discussed in the text or listed in the tables are circled, and the ADRB1 Arg389gly locus is highlighted by an arrow. Modified with permission from Taylor et al. (17) .
Disparities in Heart Failure the data can be found in Online 2) the racial differences in distribution of polymorphic variants are generally not altered in HF.
Glu298Asp, and AGTR1 A1166C, the differences in MAF allele frequencies are very different (i.e., $2.5-fold difference among races) (Online Table 1 ) and extremely different (>5-fold) for ADRB2 Thr164Ile,
Gln41Leu, and SCN5A Ser1103Tyr. Having established that AA and EA racial differences are common in signaling system polymorphisms important in HF, does this have any practical importance? First we consider potential effects on HF natural history.
DOES COMMON GENETIC VARIATION INFLUENCE HF NATURAL HISTORY IN EITHER AA OR EA POPULATIONS?
Online Table 2 lists the Online Table 1 Table 4 Online Table 4 also gives BEST placebo-treated patient data for adrenergic receptor polymorphisms listed in Online Tables 1 and 2 . For the combined EA plus AA cohort, based on the specified statistical analysis plan, there were no differences between major allele homozygotes and MAF carriers for the ADRB1 Ser49Gly, ADRB2, or ADRA2C Ins322-325Del polymorphisms, for either ACM or ACM/HFH endpoints.
In addition to pump dysfunction, the other major clinical component of HF disease progression is the development of serious arrhythmias. The SCN5A 1103Tyr variant of the Nav1.5 sodium channel is found in 6% to 9% of AA individuals but is extremely rare in EA subjects (Online Table 1 Table 6 ). In contrast, the response to fixed-dose hydralazine/isosorbide dinitrate appears to be enhanced in AA HF patients There is clearly the potential for some of the polymorphisms listed in Online Tables 1 and 2 to account for the Online Table 6 racial effects, which is given in the last column of Online Table 2 Figure 3C ) the 32% of patients who were ADRB1 Arg389Arg ( Figure 4C) had an approximately 2-fold increase in effect size, and then restriction to NYHA functional class III ( Figure 4D ) results in an approximately 3-fold increase compared with that in Figure 3C . These data suggest that differences in b-blocker/sympatholytic response exist between AA and EA patients beyond the 37% lower ADRB1 Arg389Arg genotype in AA but that additional strategies such as more precise clinical phenotyping (3) could be used to bring the AA therapeutic response in line with that of EA.
The 49Gly minor allele of ADRB1 ( Figure 1A) has an approximately 70% higher MAF in AA than in EA patients (Online Table 1 ), and this would lead to a greater degree of cardiac myocyte ADRB1 receptor down-regulation in AA HF patients that could attenuate b-blocker treatment effects by reducing ADRB1 signaling (Online Table 2 ). There are conflicting reports of effects of the ADRB1 Ser49Gly polymorphism on b-blocker effect. A recent report found that openlabel carvedilol-treated Brazilian AA patients who were 49Gly carriers had improved hospitalizationfree survival compared with 49Ser homozygotes, whereas non-black patients treated with the same 25 mg of twice daily target dose showed no differences between genotypes (31). However, in a large, 75% EA HF patient population studied prospectively and treated with carvedilol or metoprolol, no effect of ADRB1 Ser49Gly was found, including no racial buc ¼ bucindolol events/patients; HR ¼ hazard ratio; Pbo ¼ placebo events/patients. Cox modeling was unadjusted.
Disparities in Heart Failure interaction (28) . In BEST, there was no effect of the (31, 32) are not supported by biological plausibility, which would predict an attenuated effect (Online Table 2 ), at least in placebo-controlled studies. Tables 1 and 2 would predict that AA patients may be at a possible disadvantage when treated with nonselective b-blockers (Online Table 2 In advanced HF, marked sympatholysis can be Tables 1 and 2 ).
In each case, the favorable response genotype is present at a higher frequency in AA compared to EA for all-cause mortality in EA and AA patients. There were no differences in baseline NE, which ranged from 436 pg/mL to 557 pg/mL in the various groups. Abbreviations as in Figure 3 .
Taylor et al. Table 6 ).
The other device that has proved to be invaluable in HF therapy is the ICD. AA patients may have a disproportionately higher rate of ventricular arrhythmias and sudden cardiac death than EA HF patients (41) , which is likely due in part to genetic factors. The nearly exclusive presence in AAs of the Ser1103Tyr variant of SCN5A (Online Tables 1 ACKNOWLEDGMENTS The authors thank Laura Hofstatter, Rachel Rosenberg, and Morgan Deblecourt for their assistance in manuscript preparation.
